68Ga-FAPI PET/CT for diagnostic accuracy and therapeutic response assessment in bleomycin-induced pulmonary fibrosis: an integrated preclinical study
Authors:
Open Access
- 26 June 2025
- journal article
- medicine
- Published by Frontiers Media SA in Frontiers in Medicine
- Vol. 12, 1613010
Abstract
Objective: This study aimed to assess the diagnostic and therapeutic monitoring potential of 68Ga-fibroblast-activating protein inhibitor (FAPI) positron emission tomography/computed tomography (PET/CT) in bleomycin-induced pulmonary fibrosis (BIPF).Methods: A preclinical model was established through intratracheal bleomycin administration (2 mg/kg) in C57BL/6 mice, with nintedanib treatment (50 mg/kg/day) initiated at day 28 post-modeling for longitudinal evaluation. Disease progression and therapeutic response were analyzed weekly over 5 weeks using 68Ga-FAPI-04 PET/CT, complemented by histopathological validation through fibroblast activation protein (FAP) immunohistochemistry.Results: In untreated fibrotic mice, 68Ga-FAPI-04 uptake demonstrated a progressive increase, peaking at 4w (SUVmean: Left lung: 0.68 ± 0.14; Right lung: 0.65 ± 0.18). Conversely, nintedanib-treated mice exhibited an unexpected elevation in tracer uptake during late-phase imaging, but SUVR showed a decrease than untreated.Conclusion: These findings underscore 68Ga-FAPI-04 PET/CT as a sensitive tool for non-invasive assessment of BIPF early diagnosis and progression. The observed discordance in tracer uptake patterns between treatment groups highlights the need for further investigation into the temporal dynamics of antifibrotic therapy response.Keywords
This publication has 38 references indexed in Scilit:
- Betulin and Crinum asiaticum L. bulbs extract attenuate pulmonary fibrosis by down regulating pro-fibrotic and pro-inflammatory cytokines in bleomycin-induced fibrosis mice modelHeliyon, 2023
- FAP: Not Just a Biomarker but Druggable Target in Liver FibrosisCellular and Molecular Gastroenterology and Hepatology, 2023
- Target-induced activation of DNAzyme for highly sensitive colorimetric detection of bleomycin via DNA scissionRSC Advances, 2022
- Quantification of 68Ga-FAPI-04 in systemic sclerosis-associated interstitial lung diseaseThe Lancet Rheumatology, 2021
- 68Ga-FAPI-04 PET-CT for molecular assessment of fibroblast activation and risk evaluation in systemic sclerosis-associated interstitial lung disease: a single-centre, pilot studyThe Lancet Rheumatology, 2021
- [18F]FMISO PET/CT imaging of hypoxia as a non-invasive biomarker of disease progression and therapy efficacy in a preclinical model of pulmonary fibrosis: comparison with the [18F]FDG PET/CT approachEuropean Journal of Nuclear Medicine and Molecular Imaging, 2021
- Synergistic application of pulmonary 18F-FDG PET/HRCT and computer-based CT analysis with conventional severity measures to refine current risk stratification in idiopathic pulmonary fibrosis (IPF)European Journal of Nuclear Medicine and Molecular Imaging, 2019
- Vitamin C increases DNA breaks and suppresses DNA damage-independent activation of ATM by bleomycinFree Radical Biology and Medicine, 2019
- Apoptotic PET Imaging of Rat Pulmonary Fibrosis with Small-Molecule RadiotracerMolecular Imaging and Biology, 2018
- Pulmonary 18F-FDG uptake helps refine current risk stratification in idiopathic pulmonary fibrosis (IPF)European Journal of Nuclear Medicine and Molecular Imaging, 2018